Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
TipRanks on MSN
Daiichi Sankyo’s Latest Clinical Study: A Potential Game-Changer in Esophageal Cancer Treatment
Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: The study titled A Phase 1/2 Open-Label, ...
Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...
JSKN003-005 is a randomized, open-label, controlled, multicenter Phase III clinical study designed to evaluate the efficacy and safety of JSKN003 versus investigator’s choice of regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback